NOVEL USES
A method of treating, arresting or preventing a disease responsive to treatment with an anti-CD20 antibody in a patient suffering therefrom, comprising administering to the patient at least one sub-depleting dose of antiCD20 antibody is disclosed.
1 . A method of treating, arresting or preventing multiple sclerosis comprising in a human patient comprising administering an anti-CD20 antibody at:
(a) initial 3 mg dose followed by 30 mg at week one, and 30 mg at week 12; or
(b) intial 3 mg dose followed by 60 mg at week one, and 60 mg at week 12; or
(c) initial 3 mg dose followed by 60 mg at every four weeks for 24 weeks; or
(d) initial 3 mg dose followed by 30 mg at every four weeks for 24 weeks; or
(e) initial 3 mg dose, followed by 10 mg at every twelve weeks for 24 weeks; or
(f) 30 mg at week one, and 30 mg at week 12; or
(g) 60 mg at week one, and 60 mg at week 12; or
(h) 60 mg at every four weeks for 24 weeks; or
(i) 30 mg at every four weeks for 24 weeks; or
(j) 3 mg at week one, and 3 mg at week 12; or
(k) 10 mg at week one, and at every twelve weeks for 24 weeks.
2 . The method of claim 1 in which administration is subcutaneous.
3 . The method of claim 1 in which multiple sclerosis is relapse-remitting multiple sclerosis.
4 . The method of claim 1 in which multiple sclerosis is primary progressive multiple sclerosis.
5 . The method of claim 1 in which multiple sclerosis is secondary progressive multiple sclerosis.
6 . A method of treating, arresting or preventing patient spino-optical sclerosis or neuromyelitis optica in a human patient comprising administering an anti-CD20 antibody at
(a) initial 3 mg dose followed by 30 mg at week one, and 30 mg at week 12; or
(b) intial 3 mg dose followed by 60 mg at week one, and 60 mg at week 12; or
(c) initial 3 mg dose followed by 60 mg at every four weeks for 24 weeks; or
(d) initial 3 mg dose followed by 30 mg at every four weeks for 24 weeks; or
(e) initial 3 mg dose, followed by 10 mg at every twelve weeks for 24 weeks; or
(f) 30 mg at week one, and 30 mg at week 12; or
(g) 60 mg at week one, and 60 mg at week 12; or
(h) 60 mg at every four weeks for 24 weeks; or
(i) 30 mg at every four weeks for 24 weeks; or
(j) 3 mg at week one, and 3 mg at week 12; or
(k) 10 mg at week one, and at every twelve weeks for 24 weeks.
7 . The method of claim 1 in which the anti-CD20 is ofatumuamb.
8 . The method of claim 1 in which the anti-CD20 is rituximab.
9 . The method of claim 1 in which the anti-CD20 is ocrelizumab.